Fact CheckerSign in

NCT06453512Recruiting

A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema

A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema Using SCORAD, Patient Questionnaires and Skin Hydration Measurements

Source: ClinicalTrials.gov · Last updated 18 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema. The study will involve patients who are already using emollients as part of their treatment regime, switching to Doublebase Once. Patients will ideally apply the product once daily for 4 weeks and SCORAD assessments will be performed, and patient questionnaires will be completed. A subgroup of adult patients (up to 15 patients) will also undergo skin hydration measurements for the first 8 days to evaluate objective measurements of skin hydration in patients with atopic eczema. Photographs of the same, representative area of eczema will also be taken for all patients at baseline and after 4 weeks of using Doublebase Once.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
65 (estimated)
First submitted
31 May 2024
Start date
30 Oct 2024
Primary completion date
30 May 2025
Lead sponsor
Dermal Laboratories Ltd
NCT number
NCT06453512

What you commit to

  • Study type: Interventional
  • Planned participants: 65
  • From 30 Oct 2024 to the primary completion date, 30 May 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Are currently using or have used in the previous month, any systemic or topically applied antibiotics or Doublebase Once for their atopic eczema.
  • Currently participating in any other ongoing research studies or have participated in a study in the previous 30 days.

Other illness

  • Have a known history of intolerance or skin sensitivity to any of the ingredients of Doublebase Once (as identified on the patient information sheet and product labelling), or similar products.
  • Patients with any medical condition which, in the opinion of the Investigator, may adversely influence their ability to participate in the study.

Other

  • Patients, or their parents/ legal guardians, who may have difficulties completing the questionnaire, which will be written in English only.
  • Employees of the Sponsor or Investigators, or any immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of such employees.

Who the study is looking for

  • ii) Patients with atopic eczema (personal history or combined personal and familial atopy), of any severity in accordance with the NICE categorisation set out in the table below.
  • Baseline SCORAD assessment score of at least 15. iv) Patients or their parents/ legal guardians must be able to read and understand the patient information sheet and sign the Consent Form/Assent Form.
  • Patients normally managing their eczema by regular and ongoing use of leave-on emollient(s).
  • Patients who are not currently using systemic or topically applied antibiotics or Doublebase Once.
  • Patients who are willing to use Doublebase Once, once daily, as their only leave-on emollient, for 4 weeks.
  • Patients who are willing to continue to use their standard cleansing regime and/or Doublebase Once as a soap substitute for the duration of the study.
    • Additional inclusion criterion for subgroup for skin hydration assessments:
  • Baseline corneometry measurement of ≤40 arbitrary units.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Cripps Medical Centre
Coordinator of this site? Confirm its status
NottinghamUnited KingdomRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.